19 February 2016 - Ibrance is now approved for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy.

For more details, go to: http://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_expanded_fda_approval_for_ibrance_palbociclib_in_hr_her2_metastatic_breast_cancer